Major trial launches: could new drug combo extend lives for lung cancer patients?

This large, late-stage study aims to see if adding a new investigational drug (BL-B01D1) to a standard targeted therapy (osimertinib) works better than the standard therapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial will enroll 720 adults who have not yet received treatment for their advanced cancer. Researchers will compare how long patients live without their cancer getting worse and monitor side effects to determine if the combination is safe and more effective.